Retatrutide: The Triple Agonist That's Rewriting the Weight Loss Playbook
With nearly 29% average weight loss in trials—double what Ozempic delivers—Eli Lilly's triple hormone agonist is generating massive buzz. Here's what the science actually shows, when it might be available, and what those online discussions aren't telling you.